Search results
Merck Raises 2024 Profit Forecast on Strong Cancer, HPV Drugs Sales
US News & World Report· 44 minutes agoThe New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous prediction of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's ...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 16 hours agoThe RS Rating is a 1-99 measure of a stock's 12-month performance. This means Moderna stock outranks...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 17 hours agoThe RS Rating measures a stock's 12-month running performance against all other stocks. That RS...
U.S. regulators give full approval to Pfizer COVID-19 vaccine
AOL· 6 days agoThe U.S. gave full approval to Pfizer's COVID-19 vaccine on Monday, a milestone that may help lift public confidence in the shots as the nation battles ...
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for...
Morningstar· 2 days agoImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Designated ...
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
Benzinga via Yahoo Finance· 2 days ago(N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for...
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Motley Fool via Yahoo Finance· 4 days agoThe 10 stocks that made the cut could produce monster returns in the coming years. Consider when...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 21 hours agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap...
ImmunityBio stock jumps as FDA clears bladder cancer therapy (NASDAQ:IBRX)
Seeking Alpha· 2 days agoShares of ImmunityBio (IBRX) surged 33% premarket after FDA clearance of its combination therapy for...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 1 day agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...